Hepatitis B Therapeutics Market Is Expected to Increase in Value at a CAGR of 2.3% by 2021 - Increasing Number of Migrants from High-Prevalence Regions to Drive Market
Hepatitis B is an infectious liver disease caused by the Hepatitis B Virus (HBV) and characterized by acute or chronic inflammation of the liver. Despite its status as a vaccine-preventable disease, it remains a serious global health concern. Incidence tends to be higher in countries with a significant number of migrants from medium and high-prevalence countries. Approximately 350 million people worldwide are infected with chronic hepatitis B, which causes significant morbidity and mortality. Around 780,000 patients die from hepatitis B...
View full press release